Literature DB >> 32468254

Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules.

Ximin Shi1,2, Haiqun Xing1,2, Xiaobo Yang3, Fang Li1,2, Shaobo Yao4, Hui Zhang5, Haitao Zhao3, Marcus Hacker6, Li Huo7,8, Xiang Li6.   

Abstract

PURPOSE: 68Ga-FAPI-04 is a rapidly evolving PET tracer for whole-body imaging in a variety of cancers. We aimed to evaluate the diagnostic performance of 68Ga-FAPI-04 for detecting and characterizing hepatic nodules in patients with suspected carcinoma.
METHODS: Twenty-five patients showing suspicious hepatic lesions for malignancy underwent 68Ga-FAPI-04 PET. The maximum and mean standardised uptake values (SUVmax, SUVmean) were measured for all detected lesions and normal hepatic tissues, respectively. The target-to-background ratio (TBR) was calculated by dividing the lesion SUVmax with the SUVmean of non-tumour liver tissue. Lesion uptake value was correlated with the in vitro hepatic FAP expression determined by immunohistochemistry (IHC).
RESULTS: In total, 17 patients who underwent surgery or biopsy were recruited for the final analysis. A total of 28 intrahepatic malignant lesions were detected in 16 patients; the mean SUVmax was 8.36 ± 4.21 (range 2.21 to 15.86), and mean TBR was 13.15 ± 9.48 (range 2.79 to 38.12) in all detected lesions (n = 28). One benign patient showed negligible hepatic uptake (SUVmax = 0.47), whereas 75% of the primary intrahepatic hepatocellular carcinoma (HCC) lesions (n = 6) showed prominent FAP expression, 12.5% of the lesions (n = 1) showed moderate expression in stromal cells, and one showed negligible expression.
CONCLUSIONS: 68Ga-FAPI-04 showed high sensitivity in detecting hepatic malignancies, particularly in poorly differentiated forms with concordantly elevated FAP expression.

Entities:  

Keywords:  68Ga-FAPI-04; Fibroblast activating protein; Hepatic nodule; Hepatocellular carcinoma

Year:  2020        PMID: 32468254     DOI: 10.1007/s00259-020-04882-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  20 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

3.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.

Authors:  Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

5.  Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis.

Authors:  M T Levy; G W McCaughan; C A Abbott; J E Park; A M Cunningham; E Müller; W J Rettig; M D Gorrell
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

6.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 7.  The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

Authors:  Silvia Affo; Le-Xing Yu; Robert F Schwabe
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

8.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.

Authors:  Anastasia Loktev; Thomas Lindner; Walter Mier; Jürgen Debus; Annette Altmann; Dirk Jäger; Frederik Giesel; Clemens Kratochwil; Philippe Barthe; Christian Roumestand; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

Review 9.  Cholangiocarcinoma: a guide for the nonspecialist.

Authors:  Munirah Alsaleh; Zoe Leftley; Thomas A Barbera; Paiboon Sithithaworn; Narong Khuntikeo; Watcharin Loilome; Puangrat Yongvanit; I Jane Cox; Nittaya Chamodol; Richard Ra Syms; Ross H Andrews; Simon D Taylor-Robinson
Journal:  Int J Gen Med       Date:  2018-12-20

10.  The Expression of FAP in Hepatocellular Carcinoma Cells is Induced by Hypoxia and Correlates with Poor Clinical Outcomes.

Authors:  Baojia Zou; Xialei Liu; Baimeng Zhang; Yihang Gong; Chaonong Cai; Peiping Li; Jiafan Chen; Shan Xing; Jianxu Chen; Siqi Peng; Bibesh Pokhrel; Lei Ding; Linjuan Zeng; Jian Li
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

View more
  22 in total

1.  Increased [68 Ga]Ga-FAPI uptake in focal nodular hyperplasia in a patient with sigmoid colon cancer.

Authors:  Qihang Shang; Li Fu; Yizhen Pang; Tinghua Meng; Xiurong Wu; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-17       Impact factor: 9.236

2.  Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls.

Authors:  Meiqi Wu; Jing Ning; Jingle Li; Zhichao Lai; Ximin Shi; Haiqun Xing; Marcus Hacker; Bao Liu; Li Huo; Xiang Li
Journal:  J Nucl Med       Date:  2021-09-16       Impact factor: 11.082

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

4.  Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis.

Authors:  Lukas Kessler; Justin Ferdinandus; Nader Hirmas; Fadi Zarrad; Michael Nader; David Kersting; Manuel Weber; Sandra Kazek; Miriam Sraieb; Rainer Hamacher; Katharina Lueckerath; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

Review 5.  Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

Authors:  Richard L Wahl; Panithaya Chareonthaitawee; Bonnie Clarke; Alexander Drzezga; Liza Lindenberg; Arman Rahmim; James Thackeray; Gary A Ulaner; Wolfgang Weber; Katherine Zukotynski; John Sunderland
Journal:  J Nucl Med       Date:  2021-01       Impact factor: 11.082

6.  Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study.

Authors:  Donglang Jiang; Xing Chen; Zhiwen You; Hao Wang; Xiaoyun Zhang; Xiuming Li; Shuhua Ren; Qi Huang; Fengchun Hua; Yihui Guan; Jun Zhao; Fang Xie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-23       Impact factor: 9.236

7.  Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Authors:  W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

8.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

9.  Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma.

Authors:  Bingxin Gu; Xin Liu; Shuoer Wang; Xiaoping Xu; Xiaosheng Liu; Silong Hu; Wangjun Yan; Zhiguo Luo; Shaoli Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-03       Impact factor: 10.057

10.  68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma.

Authors:  Hao Wang; Wenwei Zhu; Shuhua Ren; Yanyan Kong; Qi Huang; Jun Zhao; Yihui Guan; Huliang Jia; Jinhong Chen; Lu Lu; Fang Xie; Lunxiu Qin
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.